No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
FDMT240719C17500
- 0.10
- +0.05+100.00%
15min DelayTrading Jul 19 09:30 ET
0.10High0.10Low
0.10Open0.05Pre Close1 Volume116 Open Interest17.50Strike Price10.00Turnover333.62%IV23.08%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1120Delta0.0980Gamma143.00Leverage Ratio-0.3210Theta0.0000Rho16.02Eff Leverage0.0011Vega
Intraday
- 5D
- Daily
News
BMO Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
BMO Capital analyst Kostas Biliouris maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Domino's Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results.The company reported second-quarter FY24 sales growth of 7.1% year-
Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
In the preceding three months, 5 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:FDMT), presenting a wide array of perspectives from bullish to bearish.Summarizing their recent
4D Molecular Therapeutics Is Maintained at Outperform by BMO Capital
4D Molecular Therapeutics Is Maintained at Outperform by BMO
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $38 to $82
On Jul 18, major Wall Street analysts update their ratings for $4D Molecular Therapeutics(FDMT.US)$, with price targets ranging from $38 to $82.BofA Securities analyst Tazeen Ahmad maintains with a
Express News | 4D Molecular Therapeutics Inc : BMO Cuts Target Price to $40 From $63
Comments
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
7
$4D Molecular Therapeutics(FDMT.US$ should I buy?
1
$4D Molecular Therapeutics(FDMT.US$ didnt know it jump so much..sold too early
$4D Molecular Therapeutics(FDMT.US$ Phase 2 stock offering
2
Read more